Skip to main content

Table 2 Clinical assessments and bone turnover in AS patients still using their first TNF-α blocking agent

From: The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study

Assessment Baseline 3 months P* 6 months P* 12 months P* 24 months P* 36 months P*
BASDAI (range 0 to 10) 6.0 ± 1.7 2.5 ± 1.6 0.000 2.3 ± 1.7 0.000 2.7 ± 2.1 0.000 2.5 ± 1.8 0.000 2.6 ± 1.7 0.000
ASDASCRP 3.9 ± 0.8 1.7 ± 0.7 0.000 1.6 ± 0.7 0.000 1.9 ± 0.9 0.000 1.9 ± 0.8 0.000 1.8 ± 0.8 0.000
Physician's GDA (range 0 to 10) 5 (1 to 9) 2 (0 to 5) 0.000 1 (0 to 8) 0.000 1 (0 to 7) 0.000 0 (0 to 6) 0.000 0 (0 to 3) 0.000
Patient's GDA (range 0 to 10) 6 (1 to 10) 2 (0 to 8) 0.000 2 (0 to 8) 0.000 2 (0 to 10) 0.000 2 (0 to 8) 0.000 2 (0 to 7) 0.000
ESR (mm/h) 22 (2 to 90) 5 (2 to 35) 0.000 6 (2 to 36) 0.000 7 (2 to 52) 0.000 9 (2 to 46) 0.000 8 (2 to 48) 0.000
CRP (mg/l) 16 (2 to 99) 3 (2 to 20) 0.000 3 (2 to 21) 0.000 3 (2 to 38) 0.000 3 (2 to 61) 0.000 3 (2 to 57) 0.000
BALP Z-score 0.19 (-1.64 to 3.91) 0.94 (-1.49 to 5.12) 0.000 0.48 (-1.26 to 4.37) 0.000 0.87 (-1.34 to 6.69) 0.000 0.58 (-1.46 to 6.11) 0.000 1.09 (-1.33 to 9.27) 0.000
PINP Z-score 0.36 (-1.75 to 3.63) 0.50 (-1.54 to 4.55) 0.047 0.54 (-1.47 to 5.33) 0.054 0.28 (-1.52 to 5.53) 0.102 0.57 (-1.51 to 7.17) 0.013 0.28 (-1.45 to 2.43) 0.247
sCTX Z-score -0.02 (-2.58 to 4.01) -0.74 (-2.53 to 2.29) 0.000 -0.55 (-2.25 to 3.99) 0.002 -0.45 (-2.23 to 3.11) 0.011 -0.34 (-2.15 to 4.31) 0.119 -0.70 (-2.50 to 4.15) 0.019
LS BMD Z-score -0.36 ± 1.56      0.04 ± 1.42 0.000 0.20 ± 1.39 0.000 0.48 ± 1.61 0.000
Hip BMD Z-score -0.40 ± 1.06      -0.32 ± 0.91 0.000 -0.24 ± 1.01 0.000 -0.16 ± 1.03 0.000
  1. Data of the 72 AS patients who were still using their first TNF-α blocking agent after three years were analyzed.
  2. Values are mean ± SD or median (range).
  3. See Table 1 for abbreviations.
  4. * P-value compared to values recorded at baseline.